Klingman & Associates’s Corteva CTVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$422K Buy
4,981
+67
+1% +$5.38K 0.02% 220
2026
Q1
$411K Buy
4,914
+81
+2% +$6.1K 0.02% 217
2025
Q4
$324K Buy
4,833
+192
+4% +$12.4K 0.02% 243
2025
Q3
$314K Buy
4,641
+61
+1% +$4.42K 0.02% 248
2025
Q2
$341K Buy
4,580
+58
+1% +$3.86K 0.02% 227
2025
Q1
$285K Buy
4,522
+349
+8% +$21.6K 0.02% 225
2024
Q4
$238K Buy
4,173
+106
+3% +$6.27K 0.01% 234
2024
Q3
$239K Buy
+4,067
New +$222K 0.01% 246

Other funds holding CTVA

Klingman & Associates's CTVA Position: Q2 2026 in Review

Klingman & Associates increased its Corteva (CTVA) stake by 1.4% in Q2 2026, buying an estimated $5.38K and bringing the position to 4,981 shares worth $422K. The position accounts for 0.02% of the portfolio, ranked #220.

Klingman & Associates first reported a position in CTVA in Q3 2024 and has held it in 8 quarters since. 1,491 funds tracked by Wall St. Rank hold CTVA as of Q2 2026.

  • Klingman & Associates held 4,981 shares of Corteva worth $422K as of Q2 2026.
  • Klingman & Associates bought 67 Corteva shares in Q2 2026, an estimated $5.38K.
  • Corteva made up 0.02% of Klingman & Associates's portfolio in Q2 2026, its #220 holding.
  • Klingman & Associates first reported a position in Corteva in Q3 2024 and has held it in 8 quarters since.
  • 1,491 funds tracked by Wall St. Rank held Corteva as of Q2 2026.

Based on Klingman & Associates's 13F filing for Q2 2026, filed 29 Jul 2026.